The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”)

Upadacitinib (UPA), a JAK inhibitor, is a new therapeutic option that allows patients with insufficient response to therapy with basic anti-inflammatory drugs (DMARDs) or genetically engineered biological drugs (GEBDs) to achieve the goals of therapy for rheumatoid arthritis (RA). Despite the availa...

Descripció completa

Dades bibliogràfiques

Autors principals:	V. N. Amirjanova, A. E. Karateev, E. Y. Pogozheva, A. A. Baranov, V. I. Mazurov, R. R. Samigullina, O. N. Anoshenkova, N. A. Lapkina, T. Yu. Grineva, E. L. Nasonov, A. M. Lila
Format:	Artigo
Idioma:	Russo
Publicat:	IMA PRESS LLC 2021-10-01
Col·lecció:	Научно-практическая ревматология
Matèries:	rheumatoid arthritis upadacitinib efficacy quality of life
Accés en línia:	https://rsp.mediar-press.net/rsp/article/view/3077
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!